New shot for eczema shows promise in large trial

NCT ID NCT07544862

Recruiting now Disease control Sponsor: Chengdu Kangnuoxing Biopharma,Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a new biologic drug called Stapokibart, given as a shot, for adults with moderate-to-severe atopic dermatitis (eczema). The trial will enroll 1000 people to see if the drug is safe and helps control the condition. It is an open-label study, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stapokibart (a biologic drug given as a shot under the skin)
What this could lead to: If it works, this could offer a new treatment option to control moderate-to-severe atopic dermatitis and reduce flare-ups.
What could go wrong: This is an early-stage, open-label study with no placebo group, so results may be less reliable. Side effects or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS (AD)

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.